The new BlueScreen HC assay provides a simple alternative for those screeners, profilers and safety toxicologists for whom fluorescence reporter systems are either not appropriate or not accessible, or where there is a preference for a luminescent rather than a fluorescent assay.
BlueScreen HC uses the Gaussia luciferase reporter gene which provides a flash luminescent output. Like GreenScreen HC, the assay has been developed in a 96 well microplate format can be used to screen up to four compounds at multiple dilutions on a plate. Both assays can be performed with ‘S9’ incubation, allowing the detection of progenotoxins.
To coincide with the expansion of cell-based screening services, Gentronix has also announced the introduction of its in vitro Comet assay service.
The in vitro Comet assay can provide insight into the mechanism of genotoxic damage. It is increasingly used for in vivo studies. Used as an in vitro assay, it can readily supply mechanistic information as a follow up for compounds that produce positive GreenScreen HC or BlueScreen HC results. Early indication of the mode of action of genotoxic compounds can assist in strategies to remove unwanted toxicity and reduce attrition rates in drug discovery.
The new BlueScreen HC assay is provided in kit format, or through a screening service. Gentronix offers a 2 week turn around for all service testing, and requires only low milligram quantities of compound.
Gentronix will be exhibiting at the 49th Society of Toxicology Meeting and ToxExpo to be held in Salt Lake City, Utah. 7th-11th March and look forward to welcoming you to BOOTH 1919 to discuss your needs in early toxicity detection.